Chengdu PNP Biotech Co., Ltd.

No. 13, South Section 1, Second Ring Road
Suite 709, Wuhou District, Chengdu
Sichuan 610041, P.R. China
info@pnpbiotech.com
www.pnpbiotech.com

PROPOSITION 65 STATEMENT

Magnesium Citrate Anhydrous 15% Magnesium

The California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65) requires a warning if a product exposes a person to a listed chemical above a specified safe-harbour level. This statement addresses Magnesium Citrate Anhydrous 15% Magnesium supplied by Chengdu PNP Biotech Co., Ltd.

1. Listed-chemical assessment

- Metals listed under Proposition 65 and relevant to this type of ingredient include lead, arsenic, cadmium and mercury. No other Proposition 65-listed chemical is reasonably expected to be present in this purified substance.

2. Typical heavy-metal results and derived maximum daily intake

Warning obligations are exposure-based (µg/day). Typical results from our Certificate of Analysis (ICP-MS) are increased by 30% as the calculation basis to cover normal batch-to-batch variation; a result below the limit of quantification is used as reported, without uplift. Intake (g/day) = safe harbour (µg/day) ÷ basis (µg/g), with 1 ppm = 1 µg/g.

Heavy metal	Safe harbour (µg/day)	Spec. (ppm)	Typical Result (ppm)	Basis (+30%, ppm)	Max. intake (g/day)
Lead (Pb)	MADL 0.5	≤ 0.5	0.051	0.0662	7.6 (binding)
Arsenic (As)	NSRL 10 (inorganic)	≤ 0.5	0.049	0.0638	156.7
Cadmium (Cd)	MADL 4.1	≤ 0.5	0.006	0.0073	561.6
Mercury (Hg)	0.3 (reference)	≤ 0.1	< 0.01	0.01 (LOQ)	>30.0

3. Conclusion

- The table above gives derived maximum daily intakes calculated from typical results in our Certificate of Analysis. These are screening reference values, not safety limits and not a warning determination; the customer remains responsible for the Proposition 65 assessment of its finished product. Conservative assumptions apply: total arsenic is treated as inorganic arsenic, total mercury as methylmercury, other dietary sources are excluded, and no naturally occurring exemption under 27 CCR 25501 is invoked.

This statement is provided to support our customers' compliance obligations and does not constitute legal advice.

Prepared by: Mia Yu Approved by: Charlie Wang Date: Sep. 07, 2026